Microsaic Systems (Woking, UK) has formed its first advisory group, to advise the company on where to apply microchip technology in the future. Colin Jump, CEO of Microsaic Systems, said that the company has drawn from expertise in the UK analysis and mass spectrometry arena
Microsaic Systems (Woking, UK) has formed its first advisory group, to advise the company on where to apply microchip technology in the future. Colin Jump, CEO of Microsaic Systems, said that the company has drawn from expertise in the UK analysis and mass spectrometry arena.
The majority of the advisory group come from industry and research backgrounds, comprising the Chair: Dr Steve Lane, C.Chem, FRSC, Founder & Director of SJL Strategic Sciences and former Global VP Analytical Chemistry at GSK; Prof Frank Pullen, PhD, CSci, C.Chem, FRSC, Professor of Pharmaceutical Analysis, University of Greenwich and former Senior Director of Discovery Analytical Sciences at Pfizer, UK; Mr Richard Fussell, Senior Analytical Chemist in the Chemical Safety Programme of Food and Environment Research Agency (FERA); Dr Anthony Bristow, Associate Principal Scientist, Astra Zeneca and Chair BMSS; Dr Andrew Ray, Associate Principal Scientist, AstraZeneca; Dr John Langley, Head of Characterization and Analytics, University of Southampton; Dr Neil Spooner, C.Chem, MRSC, Director, Bioanalytical Science & Development, PTS DMPK, GSK; Dr Donald Daley, Senior Director of DMPK & Physical Sciences, Argenta Discovery and former Department Director, Global Physical Chemistry and Structural Chemistry, Rhone Poulenc Rorer; and Prof Eric Yeatman, Director and co-founder of Microsaic Systems plc and Professor of Microengineering, Imperial College London. The remaining members are drawn from Microsaic’s senior management: Mr Colin Jump, CEO; Mr Peter Edwards, Technical Director, Dr Steven Wright, Principal Scientist; and Mr Jeremy Reddish, Business Development Manager.
For more information please visit www.microsaic.com
Accelerating Monoclonal Antibody Quality Control: The Role of LC–MS in Upstream Bioprocessing
This study highlights the promising potential of LC–MS as a powerful tool for mAb quality control within the context of upstream processing.
Using GC-MS to Measure Improvement Efforts to TNT-Contaminated Soil
April 29th 2025Researchers developing a plant microbial consortium that can repair in-situ high concentration TNT (1434 mg/kg) contaminated soil, as well as overcome the limitations of previous studies that only focused on simulated pollution, used untargeted metabolone gas chromatography-mass spectrometry (GC-MS) to measure their success.